BidaskClub upgraded shares of Enanta Pharmaceuticals (NASDAQ:ENTA) from a sell rating to a hold rating in a report released on Friday, November 2nd.
Other equities research analysts have also issued research reports about the company. Zacks Investment Research upgraded Enanta Pharmaceuticals from a hold rating to a buy rating and set a $105.00 price target for the company in a research note on Thursday, August 9th. JMP Securities reissued a buy rating and set a $120.00 price objective on shares of Enanta Pharmaceuticals in a report on Tuesday, July 31st. Oppenheimer set a $100.00 price objective on shares of Enanta Pharmaceuticals and gave the company a hold rating in a report on Tuesday, August 14th. Finally, UBS Group downgraded shares of Enanta Pharmaceuticals from an outperform rating to a market perform rating in a report on Wednesday, August 8th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and three have issued a buy rating to the company’s stock. The company currently has an average rating of Hold and an average price target of $104.00.
Shares of NASDAQ ENTA traded down $2.20 during midday trading on Friday, hitting $76.01. 282,550 shares of the stock traded hands, compared to its average volume of 235,103. The stock has a market capitalization of $1.64 billion, a price-to-earnings ratio of 83.53 and a beta of 1.04. Enanta Pharmaceuticals has a one year low of $44.52 and a one year high of $127.77.
In related news, insider Tim Ocain sold 25,000 shares of Enanta Pharmaceuticals stock in a transaction that occurred on Monday, October 1st. The shares were sold at an average price of $83.64, for a total transaction of $2,091,000.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Nathalie Adda sold 4,155 shares of Enanta Pharmaceuticals stock in a transaction that occurred on Thursday, September 20th. The shares were sold at an average price of $95.32, for a total transaction of $396,054.60. Following the transaction, the vice president now directly owns 4,155 shares in the company, valued at $396,054.60. The disclosure for this sale can be found here. In the last three months, insiders sold 33,310 shares of company stock valued at $2,870,644. 10.56% of the stock is owned by insiders.
Several large investors have recently bought and sold shares of the company. United Services Automobile Association lifted its position in Enanta Pharmaceuticals by 1.7% during the second quarter. United Services Automobile Association now owns 37,289 shares of the biotechnology company’s stock valued at $4,322,000 after purchasing an additional 635 shares during the period. State Board of Administration of Florida Retirement System raised its position in shares of Enanta Pharmaceuticals by 7.8% in the second quarter. State Board of Administration of Florida Retirement System now owns 8,849 shares of the biotechnology company’s stock worth $1,026,000 after acquiring an additional 640 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its position in shares of Enanta Pharmaceuticals by 22.6% in the third quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 3,747 shares of the biotechnology company’s stock worth $320,000 after acquiring an additional 690 shares during the period. Rhumbline Advisers raised its position in shares of Enanta Pharmaceuticals by 1.9% in the second quarter. Rhumbline Advisers now owns 37,550 shares of the biotechnology company’s stock worth $4,352,000 after acquiring an additional 691 shares during the period. Finally, Strs Ohio raised its position in shares of Enanta Pharmaceuticals by 7.4% in the third quarter. Strs Ohio now owns 11,600 shares of the biotechnology company’s stock worth $991,000 after acquiring an additional 800 shares during the period. Institutional investors and hedge funds own 78.05% of the company’s stock.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company's research and development focuses on disease targets: hepatitis B virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and respiratory syncytial virus.
Featured Story: How much money do you need to begin day trading?
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.